Combination therapy of infliximab and thalidomide for refractory entero-Behcet's disease: a case report
نویسندگان
چکیده
BACKGROUND Behcet's disease (BD) is a systemic inflammatory disease with the histopathological features of leukocytoclastic vasculitis that affects nearly all organs and systems. When it involves the intestine, it is called entero-Behcet's disease (entero-BD). CASE PRESENTATION Here we described a 23-year-old man with entero-BD refractory to conventional therapies who responded well to the combination therapy of infliximab, an anti-tumor-necrosis-factor (TNF)-alpha antibody, and thalidomide. After combination treatment, the patient's symptoms improved greatly and his Crohn's Disease Activity Index (CDAI) score decreased from 344 to 52 points, accompanied by a body weight increase from 53 kg to 64 kg. A follow-up endoscopy performed 10 weeks after the treatment showed significant improvement and the patient's multiple ulcers had healed well. CONCLUSION The combination therapy of infliximab and thalidomide appears to be clinically effective in a patient with refractory entero-BD. However, further studies need to be performed to evaluate the efficacy of this combination therapy.
منابع مشابه
The Effect of Infliximab Therapy on Maculopathy in Behcet's Panuveitis: A Case Report
AIM To report a case of Behcet's panuveitis and unilateral inflammatory maculopathy which was refractory to conventional immunosuppressive therapy but responded well to long-term treatment with the tumor necrosis factor-alpha inhibitor infliximab. METHODS Reporting the effect of intravenous infliximab infusion therapy for 54 weeks in a case of Behcet's panuveitis and unilateral inflammatory m...
متن کاملSwitching to Etanercept in Intestinal Behcet’s Disease Complicated by Secondary Non-response to Anti-TNF-α Antibodies
The efficacy of anti-TNF-α antibodies including infliximab and adalimumab for refractory intestinal Behcet's disease has recently been demonstrated in a series of case reports. The efficacy of switching to a different kind of anti-TNF-α agent in the face of refractoriness to one kind of anti-TNFα agent, a common practice of proven efficacy in rheumatoid arthritis, has yet not been reported for ...
متن کاملInfliximab associated with life-threatening lung infection in a patient with Behcet disease with intestinal and hematopoietic system involvement
RATIONALE Tumor necrosis factor (TNF-α) participates in the pathophysiology of Behcet's disease (BD) and myelodysplastic syndrome (MDS). Infliximab is recommaned for the most severe type of BD, however, there is little evidence for its effectiveness in BD associated MDS. PATIENT CONCERNS A 46-year-old female, initially diagnosed with intestinal BD and leukopenia was later diagnosed as MDS. Tr...
متن کاملAsymptomatic giant coronary aneurysm in an adolescent with Behcet's syndrome
OBJECTIVE Behcet's is an idiopathic multi-organ syndrome, which may have onset during childhood. Vascular involvement is uncommon, with rarely reported coronary aneurysm formation. We present a case report of a teenager girl who developed recalcitrant life-threatening Behcet's vasculitis, involving both small and large venous and arterial systems including a giant coronary aneurysm. CASE REPO...
متن کاملTreatment of a Child with Refractory Acute Myeloid Leukemia with Humanized Anti-CD33 Monoclonal Antibody: A Case Report and Review of Drug Development
Background: The induction chemotherapy regimen for acute myeloid leukemia has evolved as once induction is completed patients progress through the consolidation phase and achieve remission in 76% of cases. For patients with relapsed or refractory disease, alternative chemotherapy agents are available. Monoclonal antibody therapy with biological agents, such as the immunotoxin gemtuzumab ozog...
متن کامل